ArticlebioRxiv : the preprint server for biology2025
PLIERv2: bigger, better and faster.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gene expression analysis has long been fundamental for elucidating molecular pathways and gene-disease relationships, but traditional single-gene approaches cannot capture the coordinated regulatory networks underlying complex phenotypes; although unsupervised matrix factorization methods (e.g., PCA, NMF) reveal coexpression patterns, they lack the ability to incorporate prior biological knowledge and often struggle with interpretability and technical noise correction. Semi-supervised strategies such as PLIER have improved interpretability by integrating pathway annotations during latent variable extraction, yet the original PLIER implementation is prohibitively slow and memory-intensive, making it impractical for modern large-scale resources like ARCHS4 or recount3. Here, we introduce PLIERv2, which overcomes these constraints through a two-phase algorithmic design (an unsupervised "PLIERbase" initialization followed by a "PLIERfull" regression that incorporates priors via glmnet), rigorous internal cross-validation to tune regularization parameters for each latent variable, and efficient on-disk data handling using memory-mapped matrices from the bigstatsr package. Benchmarking on GTEx, recount2, and ARCHS4 demonstrates that PLIERv2 achieves 7×-41× speedups over PLIERv1, succeeds in modeling hundreds of thousands of samples that PLIERv1 cannot handle, and maintains or improves biological specificity of latent variables as shown by tissue-alignment and pathway enrichment analyses. By filling the gap in scalable, biologically informed latent variable extraction, PLIERv2 enables comprehensive analysis of modern transcriptomic compendia and paves the way for deeper insights into gene regulatory networks and downstream applications in translational genomics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.